Immunic Investor Relations Material
Latest events
Study Update
Immunic
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immunic Inc
Access all reports
Immunic Inc. is a clinical-stage biopharmaceutical company, developing a pipeline of selective oral immunology therapies. The company’s lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. Its other programs are IMU-935 for the restoration of the intestinal barrier in patients suffering from diseases such as inflammatory bowel disease; IMU-856 for restoration of the intestinal barrier function in patients suffering from diseases such as inflammatory bowel disease with diarrhea; and an anti-inflammatory intravenous formulation being developed to treat acute kidney injury.
Key slides for Immunic Inc
Study Update
Immunic Inc
Study Update
Immunic Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMUX
Country
🇺🇸 United States